מדד נזילות מהירה: bioAffinity Technologies (BIAF)

The confirmed price history on the chart for bioAffinity Technologies (BIAF) is currently at 1.43. The business relies on Physiocist AI testing, creating a closed-loop diagnostic cycle via cloud-based sample processing. Position stability is bolstered by patents and strict FDA oversight, although success depends on insurance reimbursements, regulatory approvals, and the willingness of medical centers to scale new laboratory protocols.

The quick ratio measures the ability of bioAffinity Technologies (BIAF) to meet its short-term obligations using cash and accounts receivable, completely excluding illiquid inventories. By analyzing this acid-test ratio, an investor assesses the risk of cash flow gaps. This is critical for bioAffinity Technologies (BIAF) when scaling robotic cancer diagnostic systems that require operational expenditures. Stable dynamics of this metric confirm the financial resilience of the business.